Treatment of Endometriosis with the Luteinizing Hormone-Releasing Hormone Agonist Nafarelin. Effect on Bone Turnover and Bone Mass

Pernille Ravn, Agneta Bergqvist, M.A. Hansen, Kirsten Overgaard, Claus Christiansen
In: Menopause · 1994 · vol. 1(1) , pp. 11???18 · doi:10.1097/00042192-199400110-00003 · W2043211128
article OA: closed CC0 ⤵ 4 in-corpus citations
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-28 ⓘ

Nafarelin monotherapy for endometriosis increased bone resorption and decreased bone mass, while combination therapy with norethisterone had less detrimental effects on bone and lipid metabolism.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-01 · read from full text ⓘ

This study evaluated the impact of nafarelin monotherapy versus combination therapy with norethisterone on bone turnover and mass in 49 premenopausal women with laparoscopically confirmed endometriosis. Participants received varying doses of nafarelin for six months, followed by a six-month washout period, during which researchers monitored biochemical markers of bone formation and resorption alongside mineral density measurements at the forearm and spine. The results indicated that nafarelin alone significantly increased bone resorption markers and caused minor decreases in bone mineral content, while the addition of norethisterone mitigated these skeletal effects and improved adverse changes in lipid profiles. This paper is centrally about endometriosis — specifically examining the metabolic side effects of hormonal suppression therapies used to treat the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

We investigated the effect of nafarelin monotherapy and nafarelin/ norethisterone combination therapy on bone turnover and bone mass. A total of 49 premenopausal women with endometriosis confirmed by laparoscopy were randomized to double-blind treatment for 6 months with 400 μg nafarelin (n = 12), 200 μg nafarelin (n = 12), or 200 μg nafarelin combined with 1.2 mg norethisterone (n = 25). All were followed for another 6 months without treatment and 47 women completed the whole study period. Parameters for bone formation (plasma bone Gla protein and serum total alkaline phosphatase) and bone resorption (fasting urinary hydroxyproline and calcium corrected for creatinine excretion) were determined at baseline and every 3 months. Bone mass was measured at baseline and every 6 months in the forearm and the spine. A significant increase in the parameters of bone resorption was observed after treatment with nafarelin monotherapy, whereas these parameters remained unchanged after combination therapy with norethisterone. A delayed increase in markers of bone formation was observed in all groups, but the response was less pronounced in the combination therapy group. In the 400 μg nafarelin group we observed a delayed 1% (p < 0.05) decrease in the bone mineral content of the forearm; no changes were observed in this region in the 200 μg nafarelin groups. Bone mineral density of the spine decreased 2–3% (p < 0.05–0.001) in all groups. In the nafarelin monotherapy groups, a significant increase in serum total cholesterol, LDL-C, and triglycerides was found. Combination therapy with norethisterone decreased this negative effect on the lipid profile. We conclude that combined nafarelin/norethisterone treatment has a less deleterious effect on bone and lipid metabolism than treatment with nafarelin alone.
Full text 2,048 characters · extracted from oa-doi-fallback · click to expand
Treatment of Endometriosis with the Luteinizing Hormone-Releasing Hormone Agonist Nafarelin. Effect on Bone Turnover and Bone Mass - Pernille Ravn - Agneta Bergqvist - Marc Allan Hansen - Kirsten Overgaard - Claus Christiansen We investigated the effect of nafarelin monotherapy and nafarelin/ norethisterone combination therapy on bone turnover and bone mass. A total of 49 premenopausal women with endometriosis confirmed by laparoscopy were randomized to double-blind treatment for 6 months with 400 μg nafarelin (n = 12), 200 μg nafarelin (n = 12), or 200 μg nafarelin combined with 1.2 mg norethisterone (n = 25). All were followed for another 6 months without treatment and 47 women completed the whole study period. Parameters for bone formation (plasma bone Gla protein and serum total alkaline phosphatase) and bone resorption (fasting urinary hydroxyproline and calcium corrected for creatinine excretion) were determined at baseline and every 3 months. Bone mass was measured at baseline and every 6 months in the forearm and the spine. A significant increase in the parameters of bone resorption was observed after treatment with nafarelin monotherapy, whereas these parameters remained unchanged after combination therapy with norethisterone. A delayed increase in markers of bone formation was observed in all groups, but the response was less pronounced in the combination therapy group. In the 400 μg nafarelin group we observed a delayed 1% (p < 0.05) decrease in the bone mineral content of the forearm; no changes were observed in this region in the 200 μg nafarelin groups. Bone mineral density of the spine decreased 2–3% (p < 0.05–0.001) in all groups. In the nafarelin monotherapy groups, a significant increase in serum total cholesterol, LDL-C, and triglycerides was found. Combination therapy with norethisterone decreased this negative effect on the lipid profile. We conclude that combined nafarelin/norethisterone treatment has a less deleterious effect on bone and lipid metabolism than treatment with nafarelin alone.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-10T10:26:17.946222+00:00
License: CC0 · commercial use OK